The Claim
Laromestrocel infusion is not associated with an increased risk of serious adverse events, hospitalizations, falls, or mortality in older adults with frailty over a nine-month period compared to placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older adults with frailty, receiving laromestrocel infusion does not lead to higher rates of serious adverse events, hospitalizations, falls, or death over nine months compared to receiving a placebo.
See the scientific wording
Laromestrocel infusion is not associated with an increased risk of serious adverse events, hospitalizations, falls, or mortality in older adults with frailty over nine months compared to placebo, indicating a favorable short-term safety profile.
Laromestrocel cells release a protein that blocks an enzyme from cutting a key receptor on blood vessel walls. This keeps the receptor active, which strengthens blood vessels and improves blood flow to muscles, especially those used for walking. Better blood flow helps muscles work longer without fatigue, which supports physical function without causing harm to the body.
What the research says
1 studyStudy: Randomized Phase 2b Dose-Escalation Trial of Stem Cell Therapy with Laromestrocel for Aging Frailty
In a study with older, frail adults, those who got the stem cell treatment didn’t have more hospital stays, falls, or deaths than those who got a fake treatment — meaning the stem cells were just as safe as the placebo over nine months.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.